UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): June 23, 2004
-------------
PRO-PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Nevada
----------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
000-32877 04-3562325
------------------------- -----------------------------------
(Commission File Number) (IRS Employer Identification No.)
189 Wells Avenue, Newton, Massachusetts 02459
---------------------------------------- ------------
(Address of Principal Executive Offices) (Zip Code)
(617) 559-0033
------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
Not Applicable
---------------------------------------------------------------
(Former Name or Former Address, If Changed Since Last Report)
Item 5. Other Events and Regulation FD Disclosure
-----------------------------------------
On June 23, 2004, Pro-Pharmaceuticals, Inc. issued a press release, which
is attached hereto as Exhibit 99.1.
Item 7. Financial Statements and Exhibits
---------------------------------
(c) Exhibits.
99.1 Press Release of Pro-Pharmaceuticals, Inc. dated June 23, 2004
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
PRO-PHARMACEUTICALS, INC.
By: /s/ David Platt
-------------------------------------
David Platt, Ph.D.
President and Chief Executive Officer
Date: June 23, 2004